Search

Displaying results 1051 - 1060 of 10000 in total
  1. Drug

    Trandolapril

    go.drugbank.com/drugs/DB00519
    ApprovedInvestigational

    It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. … Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment

    Mixtures: Trandolapril and Verapamil Hydrochloride ER, Trandolapril and Verapamil Hydrochloride ERCategories: Agents Acting on the Renin-Angiotensin System
  2. Drug

    Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10793
    ApprovedInvestigational

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: VaxigripTetra Injektionssuspension in einer Fertigspritze, Influvac Tetra Injektionssuspension in einer Fertigspritze
  3. Drug

    Ammonium chloride

    go.drugbank.com/drugs/DB06767
    ApprovedInvestigationalVet approved

    Ammonium chloride is an inorganic compound with the formula NH4Cl. It is highly soluble in water producing mildly acidic solutions.

    Mixtures: COUGH - EN, COUGH - EN PLUS
  4. Drug

    Podophyllin

    go.drugbank.com/drugs/DB09094
    Approved

    Podophyllin arrests mitosis in metaphase.

    Categories: Compounds used in a research, industrial, or household setting, Skin and Mucous Membrane Agents
  5. Drug

    Sodium glycerophosphate

    go.drugbank.com/drugs/DB09561
    Approved

    Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body [A32667]. The extent of this reaction is dependent on the activity of serum alkaline phosphatases.

    Mixtures: POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1000 ML, POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1500 ML
  6. Drug

    Insulin lispro

    go.drugbank.com/drugs/DB00046
    ApprovedInvestigational

    These biochemical changes result in a reduced tendency for self-association resulting in dissolution to a dimer and then to a monomer that is absorbed more rapidly after subcutaneous injection compared … in position B29 is replaced by proline.

    Mixtures: Humalog Mix 25 (pen), Humalog Mix 25 (pen)Categories: Drugs Used in Diabetes
  7. Drug

    Lopinavir

    go.drugbank.com/drugs/DB01601
    ApprovedInvestigational

    Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. … [L11163] Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's

    Mixtures: LOPIMUNE ® + RITONAVIR 10 MG - PELLETS EN CÁPSULAS ORALES, LOPINAVIR E RITONAVIR MYLANCategories: Antivirals used in combination for the treatment of HIV infections
  8. Target

    Vitamin K epoxide reductase complex subunit 1-like protein 1

    go.drugbank.com/bio_entities/BE0002329
    TargetHumans

    Involved in vitamin K metabolism. Can reduce inactive vitamin K 2,3-epoxide to active vitamin K, and may contribute to vitamin K-mediated protection against oxidative stress. Plays a role in vitamin K-dependent gamma-carboxylation of Glu...

    Polypeptides: Vitamin K epoxide reductase complex subunit 1-like protein 1
  9. Target

    Insulin-like growth factor-binding protein complex acid labile subunit

    go.drugbank.com/bio_entities/BE0009058
    TargetCarrierHumans

    Involved in protein-protein interactions that result in protein complexes, receptor-ligand binding or cell adhesion

    Polypeptides: Insulin-like growth factor-binding protein complex acid labile subunit
  10. Drug

    Teplizumab

    go.drugbank.com/drugs/DB06606
    ApprovedInvestigational

    Teplizumab was designed as an Fc-non-binding antibody in order to reduce the incidence of CRS. … [L44091] Fc-receptors can bind to the "tail-end" anti-CD3 antibodies in an antigen-non-specific manner and lead to severe adverse effects related to cytokine release syndrome (CRS).

    Categories: Drugs Used in Diabetes